OLMA logo

Olema Oncology Inc. (OLMA)

$7.36

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OLMA

Market cap

$644782096

EPS

-2.37

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

2.128073

Price on OLMA

Previous close

$7.56

Today's open

$7.48

Day's range

$7.08 - $7.73

52 week range

$6.24 - $36.26

Profile about OLMA

CEO

Sean P. Bohen

Employees

150

Headquarters

South San Francisco, CA

Exchange

Nasdaq Global Select

Shares outstanding

87606263

Issue type

Common Stock

OLMA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on OLMA

Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript

Olema Oncology, Inc. ( OLMA ) Olema Pharmaceuticals, Inc. UBS Global Biopharma Conference 2026 November 17, 2026 10:20 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division Well, thank you, everyone. Good afternoon.

news source

Seeking Alpha • 9 hours ago

news preview

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

news source

GlobeNewsWire • Nov 16, 2026

news preview

Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Laura Prendergast Stifel, Nicolaus & Company, Incorporated, Research Division Thanks, everyone. Sean, thank you very much for being here.

news source

Seeking Alpha • Nov 12, 2026

news preview

Olema Oncology Announces Corporate Name Change

SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” pursuant to the Company's Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to ten new employees to purchase an aggregate of 261,300 shares of the Company's common stock, effective as of November 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

news source

GlobeNewsWire • Nov 3, 2026

news preview

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

news source

GlobeNewsWire • Nov 2, 2026

news preview

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

news source

Zacks Investment Research • Oct 16, 2026

news preview

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 15, 2026

news preview

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

news source

Seeking Alpha • Sep 10, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Olema Oncology Inc.

Open an M1 investment account to buy and sell Olema Oncology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OLMA on M1